CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00820898
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:42.949005+00:00
Published At: 2017-12-05T00:00:00+00:00
Record Updated At: 2017-12-29
Results Posted At: 2017-12-05
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Recurrent Uterine Corpus Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-12-29"
protocolSection.identificationModule.nctId: "NCT00820898"
protocolSection.identificationModule.officialTitle: "A Phase II Evaluation of Gemcitabine (Gemzar\u00ae, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-12-05"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.